DERM Stock — Journey Medical Corp

Journey Medical Corp (DERM)

Updated October 16, 2026.

DERM is a Stock. Total return is -49.8% over the past 4.9 years, 124.4 points behind SPY at 74.6%.

Journey Medical Corporation is a commercial-stage pharmaceutical company that develops and commercializes dermatological treatments, including marketed products such as Qbrexza for excessive underarm sweating, Accutane for severe acne, Amzeeq and Zilxi for acne and rosacea respectively, and several other topical and oral treatments for skin conditions. The company does not currently have an established distribution schedule. Journey Medical appeals to investors seeking exposure to pharmaceutical development and commercialization in the dermatology space, rather than those focused on current income generation.

DERM performance versus SPY

Price and return data through 2026-10-16.

Total return is -49.8% over the past 4.9 years, 124.4 points behind SPY at 74.6%. Over the past year its total return — price change plus distributions reinvested — is -32.9%. Its deepest 1-year drawdown was 52.6%.

DERM key facts

Asset type

Stock

Asset class

Equity

Inception date

11/12/2021

Distribution frequency

None

Last close

$4.96 (as of 2026-10-16)

Market cap

$110,344,121

Average volume

186197.0

Beta

1.111

Payout ratio

0.0%

Forward P/E

10.2145

EPS

$-0.22

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

DERM risks and drawbacks

Total return has trailed SPY over the available window. The deepest 1-year drawdown on record here is 52.6%.

Who may consider DERM — and who may not

It is a weaker fit for investors who need monthly cash flow (DERM does not currently distribute); investors whose main goal is matching SPY total return. This is educational context, not a recommendation to buy or sell.

More on DERM

• All tickers starting with D

Tagged: Healthcare.

Frequently asked questions